Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Applied DNA Sciences ( (APDN) ) just unveiled an update.
On May 22, 2025, Applied DNA Sciences held its annual meeting of stockholders, where various proposals were voted upon. All six director nominees were elected, and key proposals, including the ratification of CBIZ CPAs P.C. as the independent accounting firm, approval of a reverse stock split, and amendments to the equity incentive plan, were approved. Additionally, a non-binding advisory vote determined that stockholder votes on executive compensation will occur every three years.
The most recent analyst rating on (APDN) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Applied DNA Sciences stock, see the APDN Stock Forecast page.
Spark’s Take on APDN Stock
According to Spark, TipRanks’ AI Analyst, APDN is a Neutral.
Applied DNA Sciences faces substantial financial and operational challenges, as indicated by declining revenues and net losses. Despite some positive strategic moves, such as focusing on LineaRx, the stock suffers from poor technical indicators and valuation metrics. The company’s ongoing financial struggles and the uncertainties highlighted in the earnings call contribute to a low overall stock score.
To see Spark’s full report on APDN stock, click here.
More about Applied DNA Sciences
Applied DNA Sciences, Inc. operates in the biotechnology industry, focusing on DNA-based technology solutions. The company provides products and services for supply chain security, anti-counterfeiting, and anti-theft technology, with a market focus on protecting brands and ensuring product authenticity.
Average Trading Volume: 1,328,055
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.88M
Learn more about APDN stock on TipRanks’ Stock Analysis page.